The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility

Tai Kiuchi(King's College London), Tony Ng(King's College London), Natalie Woodman(London Cancer), Boris Ν. Kholodenko(University College Dublin), Katherine Lawler(University of Cambridge), Pierfrancesco Marra(King's College London), Simon P. Poland(King's College London), Ykelien L. Boersma(University of Zurich), Jody Barbeau(King's College London), Michael A. Simpson(King's College London), Viviane Devauges(King's College London), Yosef Yarden(Weizmann Institute of Science), Simon Ameer‐Beg(King's College London), Lan K. Nguyen(Australian Research Council), Brian Burford(Guy's Hospital), Martyn Winn(Science and Technology Facilities Council), Cheryl Gillett(King's College London), Daniel J. Rolfe(Rutherford Appleton Laboratory), Elena Ortíz-Zapater(Universitat de València), Emanuele de Rinaldis(Target (United States)), James Monypenny(King's College London), Dimitra Dafou(Aristotle University of Thessaloniki), Gilbert O. Fruhwirth(King's College London), George Santis(Guy's Hospital), Andreas Plückthun(University of Zurich), Andrew Tutt(Institute of Cancer Research), Daniel R. Matthews(King's College London), Marisa L. Martin-Fernandez(Rutherford Appleton Laboratory), William J. Gullick(The Honourable Society of Lincoln's Inn), Oana Coban(King's College London), Sarah E. Pinder(St Thomas' Hospital), Peter J. Parker(King's College London)
Science Signaling
August 19, 2014
Cited by 63


Related Papers